V
Valerie M. Jansen
Researcher at Vanderbilt University Medical Center
Publications - 32
Citations - 964
Valerie M. Jansen is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 12, co-authored 25 publications receiving 657 citations. Previous affiliations of Valerie M. Jansen include Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Luigi Formisano,Yao Lu,Alberto Servetto,Ariella B. Hanker,Ariella B. Hanker,Valerie M. Jansen,Joshua A. Bauer,Dhivya R. Sudhan,Dhivya R. Sudhan,Angel Guerrero-Zotano,Sarah Croessmann,Yan Guo,Paula Gonzalez Ericsson,Kyungmin Lee,Mellissa J. Nixon,Luis J. Schwarz,Melinda E. Sanders,Teresa C. Dugger,Marcelo Rocha Cruz,Amir Behdad,Massimo Cristofanilli,Aditya Bardia,Joyce O'Shaughnessy,Rebecca J. Nagy,Richard B. Lanman,Nadia Solovieff,Wei He,Michelle Miller,Fei Su,Yu Shyr,Ingrid A. Mayer,Justin M. Balko,Carlos L. Arteaga,Carlos L. Arteaga +33 more
TL;DR: It is shown that FGFR1 amplification is a resistance mechanism to CDK4/6 inhibitor and endocrine therapy and that combined treatment with FGFR, CDK 4/6, and anti-estrogens is a potential therapeutic strategy in Era+ breast cancer tumors.
Journal ArticleDOI
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
Valerie M. Jansen,Neil E. Bhola,Joshua A. Bauer,Luigi Formisano,Kyungmin Lee,Katherine E. Hutchinson,Agnieszka K. Witkiewicz,Preston D. Moore,Monica V. Estrada,Violeta Sanchez,Paula Gonzalez Ericsson,Melinda E. Sanders,Paula R. Pohlmann,Michael J. Pishvaian,David A. Riddle,Teresa C. Dugger,Wenyi Wei,Erik S. Knudsen,Carlos L. Arteaga +18 more
TL;DR: A kinome-wide siRNA screen was used to identify kinases that, when downregulated, yield sensitivity to the ribociclib inhibitor, and highlighted a role for the PI3K-PDK1 signaling pathway in mediating acquired resistance to CDK4/6 inhibitors.
Journal ArticleDOI
Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.
Teemu P. Miettinen,Julien Peltier,Julien Peltier,Anetta Härtlova,Anetta Härtlova,Marek Gierlinski,Valerie M. Jansen,Matthias Trost,Matthias Trost,Mikael Björklund +9 more
TL;DR: Thermal proteome profiling identifies the proteasome and ECM29 protein as mediators of palbociclib activity in breast cancer cells and finds that ECM 29 mRNA levels are predictive of relapse‐free survival in Breast cancer patients treated with endocrine therapy.
Journal ArticleDOI
Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer
Luigi Formisano,Luigi Formisano,Kimberly M. Stauffer,Christian D. Young,Neil E. Bhola,Angel Guerrero-Zotano,Valerie M. Jansen,Monica M. Estrada,Katherine E. Hutchinson,Jennifer M. Giltnane,Luis J. Schwarz,Yao Lu,Justin M. Balko,Olivier Deas,Stefano Cairo,Jean Gabriel Judde,Ingrid A. Mayer,Melinda E. Sanders,Teresa C. Dugger,Roberto Bianco,Thomas Stricker,Carlos L. Arteaga +21 more
TL;DR: The data suggest the ERα pathway remains active in estrogen-deprived ER+/FGFR1–amplified breast cancers, and these tumors are endocrine resistant and should be candidates for treatment with combinations of ER and FGFR antagonists.
Journal ArticleDOI
Treatment of Triple Negative Breast Cancer With TORC1/2 Inhibitors Sustains a Drug-resistant and Notch-dependent Cancer Stem Cell Population
Neil E. Bhola,Valerie M. Jansen,James P. Koch,Hua Li,Luigi Formisano,Janice A. Williams,Jennifer R. Grandis,Carlos L. Arteaga,Carlos L. Arteaga +8 more
TL;DR: Targeting the FGFR-mitochondrial metabolism-Notch1 axis prevents resistance to TORC1/2 inhibitors by eradicating drug-resistant CSCs in TNBC, and may thus represent an attractive therapeutic strategy to improve drug responsiveness and efficacy.